AASLD Briefs: Hepatitis C
Presentations at the American Association for the Study of Liver Diseases conference included anticipated data from Gilead in hepatitis C genotype 3 patients, results from the COSMOS trial pairing Gilead’s sofosbuvir with Janssen’s simeprevir, Phase II data for Merck’s two-drug DAA combo and findings from an HCV collaboration by Boehringer Ingelheim and Presidio.
You may also be interested in...
DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.